CVRx (CVRX) Registration Filing summary

Company overview and business model

• Commercial-stage medical device company developing minimally invasive neuromodulation solutions for cardiovascular disease.

• Flagship product Barostim is FDA-approved for heart failure (HF) and delivers electrical pulses to baroreceptors to improve symptoms.

• Focused on heart failure with reduced ejection fraction (HFrEF), targeting a significant unmet need for device-based therapies.

• Estimated annual market opportunity for HFrEF is $2.2 billion in the U.S. and $2.8 billion in select European markets.

Financial performance and metrics

• Incorporates by reference annual and quarterly SEC filings, including the 2024 10-K and 2025 10-Qs, for detailed financial data.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement for each offering.